Risk of thrombosis in patients with antiphospholipid antibodies and factor V Leiden mutation

Journal of Rheumatology

Volumn 26, Issue 3, 1999, Pages 588-590

  Pablos, José L ^a   Caliz, Rafael A ^b   Carreira, Patricia E ^a   Atsumi, Tatsuya ^b   Serrano, Lourdes ^a   Amengual, Olga ^b   Santiago, Begoña ^a   Khamashta, Munther A ^b   Hughes, Graham R V ^b   Gomez Reino, Juan J ^c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Anticardiolipin antibodies; Factor V genetics; Protein C; Systemic lupus erythematosus

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; PHOSPHOLIPID ANTIBODY;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; ARTERIAL OCCLUSIVE DISEASES; FACTOR V; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; POINT MUTATION; RECURRENCE; RISK FACTORS; SPAIN; VENOUS THROMBOSIS;

EID: 0033053726     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Hughes GRV. The antiphospholipid syndrome: ten years on. Lancet 1993;342:341-4.
2. Asherson MA, Khamashta MA, Ordi-Ros J, et al. The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine 1989;68:366-74.
3. Love PE, Santoro SA. aPL: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990;112:682-98.
4. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-22.
5. Koster T. Rosendaal FR, de Ronde H. Briët E. Vanderbroucke JP. Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993;342:1503-6.
6. Dahlbäck B, Carlsson M. Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-8.
7. Voorberg J, Roesle J, Koopman R, et al. Association of idiopathic venous thromboembolism with single-point mutation at Arg 506 of factor V. Lancet 1994;343:1535-6.
8. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
9. Vanderbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7.
10. Hirsch DR, Mikkola KM, Marks PW, et al. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. Am Heart J 1996;131:1145-8.
11. Ruiz Argüelles GJ, Garcés-Eisele J. Alarcón-Segovia D. Ruiz Argüelles A. Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome. Blood Coagul Fibrinolysis 1996;3:344-8.
12. Dizon-Thownson D, Hutchinson C, Silver R, Branch DW, Ward K. The factor V Leiden mutation which predisposes to thrombosis is not common in patients with antiphospholipid syndrome. Thromb Haemost 1995;74:1029-31.
13. Montaruli B, Borchiellini A, Tamponi G, et al. Factor V Arg 506 -Gln mutation in patients with aPL. Lupus 1996:5:303-6.
14. Sasso EH, Suzuki LA, Thompson AR, Petri MA. Hereditary resistance to activated protein C: an uncommon risk factor for thromboembolic disease in lupus patients with antiphospholipid antibodies. Arthritis Rheum 1997;40:1720-1.
15. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
16. Gharavi AE, Harris EN, Asherson RA. Hughes GRV. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis 1987;46:1-6.
17. Harris EN, Gharavi AE, Patel SP, Hughes GRV. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987;68:215-22.
18. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994;1536-8.
19. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
20. Brenner B, Vufsons SL, Lanir N, Nahir M. Coexistence of familial antiphospholipid antibody and factor V Leiden: impact on thrombolic diathesis. Br J Haematol 1996;94:166-7.
21. Fijnheer R, Horbach DA, Donders RCJM, et al. Factor V Leiden, aPL and thrombosis in systemic lupus erythematosus. Thromb Haemost 1996;76:514-7.
22. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-7.
23. Simioni P, Prandoni P, Lensing AWA, et al. The risk of recurrent thrombosis in patients with an Arg 506-Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997;336:399-403.
24. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley & Sons; 1981.